Loading...
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
BACKGROUND: Glioblastoma ranks among the most lethal cancers, with current therapies offering only palliation. Paracrine vascular endothelial growth factor (VEGF) signaling has been targeted using anti-angiogenic agents, whereas autocrine VEGF/VEGF receptor 2 (VEGFR2) signaling is poorly understood....
Na minha lista:
| Udgivet i: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6176801/ https://ncbi.nlm.nih.gov/pubmed/29939339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy103 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|